Asciminib, chronic myeloid leukemia, Novartis AG, Ph+ CML, Philadelphia chromosome, Scemblix

Asciminib is approved for Philadelphia chromosome-positive chronic myeloid leukemia

Nov 2021: Asciminib (Scemblix, Novartis AG) was given accelerated approval by the Food and Drug Administration for patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) who had pr..

BALL, Brexucabtagene autoleucel, Kite Pharma, Tecartus, ZUMA-3

Brexucabtagene autoleucel is approved by FDA for relapsed or refractory B-cell precursor acute lymphoblastic leukemia

October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). In..

Asparaginase erwinia chrysanthemi, Jazz Pharmaceuticals, JZP458-201, NCT04145531, Rylaze

FDA has approved asparaginase erwinia chrysanthemi (recombinant) for leukaemia and lymphoma

August 2021: The Food and Drug Administration has approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as part of a multi-agent chemotherapeutic regimen for the treatment of acute lym..

Avapritinib, Ayvakit™, Blueprint Medicines Corp, EXPLORER, hematological neoplasm, NCT02561988, NCT03580655, PATHFINDER

Avapritinib has been approved by the FDA for advanced systemic mastocytosis

August 2021: The FDA approved avapritinib (AyvakitTM, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an ..

BMS, Breyanzi, CAR - T Cell therapy, CAR T-Cell, CART therapy, USFDA

Breyanzi – New CAR T-Cell therapy from BMS

July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Food and Drug Administration (US..

Leukemia treatment options

Because leukemia classification and prognosis stratification are complex, there is no one-size-fits-all treatment method, and it is necessary to combine careful classification and prognosis stratification to formulate treatment p..

MD Anderson cancer center treatment story of a leukemia patient

Eddle and Pearlie Saddler, as his wife Pearlie hopes, "enjoy a regular life" in their South Carolina town. When they rested, Saddlers volunteered and participated in the service in the church. "We go there often, especially Eddi..

Study finds new ideas for leukemia treatment

A new study from McMaster University in Canada said that it has discovered a new treatment strategy for acute myeloid leukemia. By stimulating the production of fat cells in the bone marrow and adjusting the bone marrow microenvir..

AstraZeneca targeted drug Acalabrutinib has a new way to treat chronic lymphocytic leukemia

Acalabrutinib is a second-generation tyrosine kinase (BTK) inhibitor, a newer drug that can improve the survival of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).The researchers believe that BTK inhibitors comb..

Guideline for the treatment of mixed phenotype acute leukemia

A study conducted at the Los Angeles Children ’s Hospital is providing the best treatment for a rare invasive leukemia called mixed phenotype acute leukemia (MPAL).This study (a 20-year quantitative synthesis of the scientific l..